Jae Woo Lee1, Su Bong Nam1, Seong-Jang Kim2,3,4. 1. Department of Plastic and Reconstructive Surgery, Pusan National University School of Medicine, Yangsan, Republic of Korea. 2. Department of Nuclear Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea, growthkim@daum.net. 3. Biomedical Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea, growthkim@daum.net. 4. Department of Nuclear Medicine, College of Medicine, Pusan National University, Yangsan, Republic of Korea, growthkim@daum.net.
Abstract
BACKGROUND: The purpose of the current study was to investigate the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) or PET/computed tomography (PET/CT) for the detection of recurrent disease after treatment of malignant melanoma (MM) through a systematic review and meta-analysis. METHODS: The PubMed and EMBASE databases, from the earliest available date of indexing through December 31, 2018, were searched for studies evaluating the diagnostic performance of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic (SROC) curves. RESULTS: Across 14 results from 11 studies, the pooled sensi-tivity for 18F-FDG-PET or PET/CT was 0.94 (95% confidence interval [CI] 0.90-0.97) with heterogeneity (I2 = 57.95) and a pooled specificity of 0.91 (95% CI 0.88-0.93) without heterogeneity (I2 = 27.24). LR syntheses gave an overall LR+ of 10.4 (95% CI 7.7-14.2) and an LR- of 0.06 (95% CI 0.04-0.11). The pooled diagnostic odds ratio was 162 (95% CI 94-280). The hierarchical SROC curve indicated that the area under the curve was 0.96 (95% CI 0.93-0.97). In meta-regression analysis, no definite variable was the source of the study heterogeneity. CONCLUSION: The current meta-analysis showed a high sensitivity and specificity of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM. The LR scattergram indicated that 18F-FDG-PET or PET/CT is useful for exclusion and confirmation of recurrent disease after treatment of MM.
BACKGROUND: The purpose of the current study was to investigate the diagnostic performance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) or PET/computed tomography (PET/CT) for the detection of recurrent disease after treatment of malignant melanoma (MM) through a systematic review and meta-analysis. METHODS: The PubMed and EMBASE databases, from the earliest available date of indexing through December 31, 2018, were searched for studies evaluating the diagnostic performance of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM. We determined the sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic (SROC) curves. RESULTS: Across 14 results from 11 studies, the pooled sensi-tivity for 18F-FDG-PET or PET/CT was 0.94 (95% confidence interval [CI] 0.90-0.97) with heterogeneity (I2 = 57.95) and a pooled specificity of 0.91 (95% CI 0.88-0.93) without heterogeneity (I2 = 27.24). LR syntheses gave an overall LR+ of 10.4 (95% CI 7.7-14.2) and an LR- of 0.06 (95% CI 0.04-0.11). The pooled diagnostic odds ratio was 162 (95% CI 94-280). The hierarchical SROC curve indicated that the area under the curve was 0.96 (95% CI 0.93-0.97). In meta-regression analysis, no definite variable was the source of the study heterogeneity. CONCLUSION: The current meta-analysis showed a high sensitivity and specificity of 18F-FDG-PET or PET/CT for the detection of recurrent disease after treatment of MM. The LR scattergram indicated that 18F-FDG-PET or PET/CT is useful for exclusion and confirmation of recurrent disease after treatment of MM.